Lung Cancer News and Research

Latest Lung Cancer News and Research

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera enhances innate immune responses to Imprime PGG drug candidate

US underestimated its progress in war on cancer, say Dartmouth researchers

US underestimated its progress in war on cancer, say Dartmouth researchers

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Smoking and cancer: an interview with Dr. Lewis Foxhall, VP of Health Policy, University of Texas MD Anderson Cancer Center

Smoking and cancer: an interview with Dr. Lewis Foxhall, VP of Health Policy, University of Texas MD Anderson Cancer Center

Lifestyle changes and screening tools prove to reduce cancer risk, says doctor

Lifestyle changes and screening tools prove to reduce cancer risk, says doctor

Lung cancer incidence rates decrease more rapidly among U.S. men and women

Lung cancer incidence rates decrease more rapidly among U.S. men and women

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

Nano-luteolin has immense potential for future studies of chemoprevention, say researchers

Nano-luteolin has immense potential for future studies of chemoprevention, say researchers

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Cancer statistics 2014 finds steady declines in death rates

Cancer statistics 2014 finds steady declines in death rates

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

New guidelines provide screening recommendations for people at higher risk of developing lung cancer

New guidelines provide screening recommendations for people at higher risk of developing lung cancer

Viewpoints: Rethinking what health insurance should cover; Sen. Johnson suing over congressional health plan; Medicaid's unsung success

Viewpoints: Rethinking what health insurance should cover; Sen. Johnson suing over congressional health plan; Medicaid's unsung success

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Researchers work on alternative therapy to boost immune system of patients with lung cancer

ACR supports USPSTF recommendations for CT lung cancer screening in high-risk patients

ACR supports USPSTF recommendations for CT lung cancer screening in high-risk patients

Controlling tobacco marketing may reduce number of smokers by one-third

Controlling tobacco marketing may reduce number of smokers by one-third

US Task Force recommends lung-cancer screening for high-risk adults

US Task Force recommends lung-cancer screening for high-risk adults

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.